Adhera Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow17.05%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ATRX is 17.05%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside Adhera Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ATRX currently prints 17.05% for ROE, while the sector average sits near -100.59%. That is roughly 116.9% above the sector mean. Large gaps often invite a closer look at Adhera Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Adhera Therapeutics converts resources into returns. At 17.05%, ATRX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ATRX's ROE (17.05%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Adhera Therapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
